Therefore, monotherapy with PARP inhibitors will not be possible for all cancers, but combined with DNA damaging agents this provides a novel treatment strategy that can widen the therapeutic window for many forms of cancer and increase overall survival. This evidence concerns the gene PARP1 and cancer.